Translink in Armagh holding stem cell registration event in memory of Gavin McNaney – Armagh i

Gavin McNaney, who passed away two years ago.

Translink are hosting a blood stem cell registration event and coffee morning this Saturday as part of the Somebodys Stranger campaign, in memory of Armagh man Gavin McNaney, who passed away two years ago.

It will take place from 10am until 2pm and it is a painless process which could potentially save a life.

Former St Catherines College teacher Gavin was just 37 years of age when he passed on November 18, 2017.

He had been diagnosed with Acute Lymphoblastic Leukaemia whilst teaching in Dubai.

Gavin spent months in hospital undergoing treatment and had a bone marrow transplant in London.

But after contracting a common cold and an infection to his lungs, his life was sadly cut short and he passed away peacefully with mum and dad, Nuala and Pat, by his side.

Friend Karl McQuaid has been raising funds and awareness after the passing of his life-long friend, whom he had first met when they both attended St Patricks Grammar School in Armagh.

He has been running registration events as part of his Somebodys Stranger campaign for nine months in Gavins memory and is keen to advise people just how easy it is to register .

He who would like to thank Leanne Armstrong and her colleagues at Translink for inviting them to come along told Armagh I : Joining the stem cell register is quick, easy and pain-free.

Potential donors have a swab taken of the inside of their cheeks with the whole process taking just a few minutes. They will then be added to DKMSs worldwide database and could be contacted at any time should they be a genetic match for a blood cancer sufferer anywhere in the world.

Those lucky enough to be a match would then be asked to donate their stem cells in a pain-free procedure similar to giving blood. This could save the life of the cancer sufferer.

Donations are at your own discretion at the event with all proceeds going to Leukaemia & Lymphoma NI Northern Irelands only charity dedicated to fighting blood cancers.

Those willing to join the register should be in general good health and aged between 18 and 55.

All are urged to come along on Saturday morning, when the city will be full of revellers for the annual Georgian Day event. Please take time to come along to the bus station and help make a huge difference.

See more here:
Translink in Armagh holding stem cell registration event in memory of Gavin McNaney - Armagh i

Comprehensive Research on Joint Pain Injections Market Report Offers Consumption, Production, CAGR, Market Size, Profit Margin And Revenue By 2028 -…

The report titled as a globalJoint Pain Injections Market Research Report: has recently added by MarketResearch.biz to get a stronger and effective business outlook. It provides a comprehensive analysis of different attributes of industries such as size, threats, growth ratio, opportunities, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the business owners, readers, and industry experts. The industry profiles discussed in the Joint Pain Injections report further identifies market profit, segmentation, and rival landscape and offers forecast data on industry performance and trends for the period 2019 to 2028. The detailed report offers analyses about a particular market situation within a geographic region.

The Joint Pain Injections Market focuses on the regional markets of Europe, Asia-Pacific, North America, Middle East & Africa, and Latin America. Also, the major details such as product types manufactured, production values, gross margins, production capacities, global share, company contact information, manufacturing processes, cost structures, etc. are included. A number of analytical tools, such as Porters Five forces Analysis and SWOT Analysis, have been used to provide an accurate understanding of this market.

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures:Download PDF

The scope of the Joint Pain Injections Market Report ranges from market eventualities to comparative ratings between the major players, prices, and income of the relevant market regions. It offers a holistic view of the strategic dynamics of the industry. Some of the top players involved in the market are profiled completely in a systematic manner.

Some of the key players are: Allergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

Quantitative information includes Joint Pain Injections Market estimates & forecast for an upcoming year, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and year-on-year growth analysis, consumption estimates, price estimation, and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries. Qualitative information will discuss the key factors driving the restraining the growth of the market.

Joint Pain Injections Market has been segmented as:

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Inquire/Speak To Expert for Further Detailed Information About Joint Pain Injections Report:https://marketresearch.biz/report/joint-pain-injections-market/#inquiry

Key questions answered in the report

What will be the size of the market in terms of value and volume in the next 10 years?

Which segment is currently lead the market?

In which region will the market have the highest growth rate?

Which players will take the lead in the market?

What are the key drivers and restraints of the markets growth?

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/joint-pain-injections-market/#request-for-customization

Media Contact:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

See the original post here:
Comprehensive Research on Joint Pain Injections Market Report Offers Consumption, Production, CAGR, Market Size, Profit Margin And Revenue By 2028 -...

ENCORE: Why There Are So Few Black Men In Medicine; Family of Stem Cell Donor Connects With Recipient 20 Years Later; Forecasting Volcanic Eruptions -…

Last year, fewer than 4% of incoming medical students in Illinois were black men. Today: whats behind that number,and what should be done about it. Plus,decades ago, a cutting edge stem cell treatment from umbilical cord blood saved one Illinois woman's life. And earlier this year, she met her donor and his parents for the first time.And, wetalk to a University of Illinois geology professor about her work, on how to better forecast volcanic eruptions

Black Men In Medicine

Last year, fewer than 4% of incoming medical students here in Illinois were black men. That number can be surprising on the surface, but it could also have more serious health implications for all African-American men.

And the path to medicine comes with many obstacles. Some students dont get the support they need beforehand and even if they do, going to med school is incredibly expensive.

Stephanie Whiteside reported on this for Illinois Newsroom. And Dr. Don Arnold is Chief of Surgery at Herrin Hospital, just outside of Carbondale.

They both spoke with Brian Moline this past spring.

Family of Stem Cell Donor Connects With Recipient 20 Years Later

In 1994, DaniaDavey and her husband made an important decision. Although she didnt quite realize how important it was at the time, that decision would save a young womans life hundreds of miles away.

That woman is Holly Becker, who was 24 when she received a stage 4 cancer diagnosis. Hollys oncologist at Loyola Medicine in Maywood, Illinois decided to try a cutting edge treatment at the time in the 90s: a stem cell transplant from donated umbilical cord blood.

That cord blood came from Danias son Patrick. It was donated and frozen the day he was born in New York.

Holly is now cancer free. And she met the Daveys earlier this year in Illinois. Its thought to be one of the first times a stem cell donor from umbilical cord blood has met the recipient.

Dania Davey now lives in New York. Holly Becker is in the Chicago suburbs, along with her oncologist, Dr. Patrick Stiff from Loyola University Medical Center.

The three of them spoke with Brian Moline earlier this year.

Forecasting Volcanic Eruptions

When it comes to forecasting severe weather events like hurricanes, tornadoes or earthquakes, accuracy is key. Knowing what to expect and when to expect it can mean the difference between life and death.

Now, researchers at the University of Illinois are part of a new study looking at ways we can better forecast volcanic eruptions. Theyve been studying one which happened in Alaska back in 2008,which traditional forecasting models missed.

Researchers are now using new computer models to paint a more accurate picture about if and when we can expect volcanic eruptions.

Trish Gregg is a geology professor at the University of Illinois. She spoke with Brian Moline back in September.

See more here:
ENCORE: Why There Are So Few Black Men In Medicine; Family of Stem Cell Donor Connects With Recipient 20 Years Later; Forecasting Volcanic Eruptions -...

Personalized Stem Cells, Inc. Sponsors Arthritis Foundation Event in Los Angeles – PR Web

It is an honor to help support the Arthritis Foundation and to work closely with the Orthohealing Center.

POWAY, Calif. (PRWEB) November 26, 2019

Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, recently sponsored an event put on by the Arthritis Foundation and hosted by Dr. Steven Sampson and Dr. Danielle Aufiero of the Orthohealing Center in Los Angeles, California. The event, which took place on October 23, 2019, highlighted the ongoing efforts to promote research, educate the public, and provide support to people with arthritis.

Event attendees included medical doctors, physical therapists, chiropractors, and other medical professionals. Dr. Sampson presented current and evolving regenerative and stem cell therapies, including PSCs FDA approved clinical trial to treat osteoarthritis in the knee with a persons own stem cells. The Orthohealing Center is one of several approved clinical trial sites and is currently screening and enrolling patients in the clinical trial.

PSC CEO, Michael Dale, stated, It is an honor to help support the Arthritis Foundation and to work closely with the Orthohealing Center. The Foundation and the Orthohealing Center have worked together for many years advocating and spreading awareness for arthritis patients.

PSC provides stem cell therapy for clinical trial investigators and their patients, working within the FDA cell therapy regulations in order to assure consistent manufacturing, quality tested cells, as well as clinical trial and manufacturing oversite for safety and efficacy. PSC was founded by Robert Harman, DVM, MPVM and Michael Dale, both of whom also co-founded VetStem Biopharma and are both experienced serial entrepreneurs.

About Personalized Stem Cells, Inc.Personalized Stem Cells was formed in 2018 to advance and legitimize human regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patients own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing cGMP manufactured, quality tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine.

Share article on social media or email:

Read this article:
Personalized Stem Cells, Inc. Sponsors Arthritis Foundation Event in Los Angeles - PR Web

Trial cancer treatment in Wichita – KAKE

I-70 reopens in NW Kansas written by KAKE Newskake.news

Forecasters said that snow parts of northwest Kansas was falling at a rate of 1 to 2 inches per hour, and near blizzard conditions were possible.

Prosecutors have charged three people with first-degree murder in the shooting death of a 17-year-old boy in Wichita.

SafeHome.orgreleased a study on Friday that says Kansas is the 7th smartest state in the country.

There's a major medical break-through in the world of cancer treatment. No more chemotherapy or radiation; doctors in Wichita are using patients' own blood cells to fight off cancer, and it's working. 62-year-old David Butler's appointments at the Cancer Center of Kansas are coming to an end. It's been two long years for him - in 2017, stomach pain led doctors to discover 13 tumors inside his abdomen. Butler went through months of chemotherapy, then stem cell therapy. But the cancer ...

Authorities in Colorado have charged two people with animal cruelty after video showed a horse being dragged behind a pickup truck.

The latest list of school and weather-related closings and delays.

It's been a couple weeks since we set our clocks back an hour. If you're still feeling the effects of the time change, you're not alone. That has a growing number of Kansans saying it's time to end the twice a year time shuffle.

An accident shut down part of the Kansas Turnpike Tuesday night in Butler County. It happened just before 10 p.m. Tuesday after a two-vehicle accident near the Towanda Service Area.

Authorities say a wildfire in northwest Oklahoma is threatening dozens of home and forced communities to evacuate.

Jory Konrade's funeral service will be held at 11 a.m. Wednesday at CrossPoint Church in Hutchinson.

See the original post here:
Trial cancer treatment in Wichita - KAKE

AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore…

VALENCIA, Calif., MELBOURNE, Australia & AURORA, Colo.--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine announced today a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders.

The partnership will pair AVITA Medicals patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Centers innovative, patent-pending combined reprogramming and gene-editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), AVITA Medical retains the option to exclusively license technologies emerging from the partnership for further development and commercialization. The Gates Center team is further supported by the EB Research Partnership in New York, the Los Angeles-based EB Medical Research Foundation, the London-based Cure EB Charity, and government grants in a collaborative effort to rapidly develop and translate this technology to the clinic for meaningful impact on patient lives.

The Gates Center is a leader in developing therapeutic approaches for genetic skin diseases. Researchers at the Gates Center have developed a powerful new approach for treating genetic skin disorders and improving the lives of patients with epidermolysis bullosa, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical and adjunct professor at the Gates Center for Regenerative Medicine. We look forward to collaborating with the team at the Gates Center on the expanded use of our technology. This agreement marks an important milestone in AVITAs mission to harness the potential of regenerative medicine to address unmet medical needs across a broad range of dermatological indications, including genetic disorders of the skin.

Epidermolysis bullosa is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. There are no approved curative therapies, and current treatment is palliativefocused primarily on pain and nutritional management, itching relief, wound care, and bandaging.

Its very exciting to partner with AVITA Medical to help advance our epidermolysis bullosa program, said Director of the Gates Center for Regenerative Medicine Dr. Dennis Roop. Were looking forward to exploring a novel approach to delivering gene-edited skin cells to patients that addresses current treatment challenges.

We believe that Spray-On Skin Cells technology combined with our genetically corrected cells has the potential to be game changing in the treatment of this disease. This combination could reduce time to treatment, lower manufacturing complexity, reduce costs, and improve patient outcomes, said Dr. Ganna Bilousova, assistant professor of dermatology, who is a co-principal investigator on this research program.

ABOUT THE CHARLES C. GATES CENTER FOR REGENERATIVE MEDICINE

The Charles C. Gates Center for Regenerative Medicine was established in 2006 with a gift in memory of Denver industrialist and philanthropist Charles C. Gates, who was captivated by the hope and benefit stem cell research promised for so many people in the world. The Gates Center aspires to honor what he envisionedby doing everything possible to support the collaboration between basic scientific researchers and clinical faculty to transition scientific breakthroughs into clinical practice as quickly as possible.

Led by Founding Director Dennis Roop, Ph.D., the Gates Center is located at the University of Colorados Anschutz Medical Campus, the largest new biomedical and clinical campus in the United States. Operating as the only comprehensive Stem Cell Center within a 500-mile radius, the Gates Center shares its services and resources with an ever-enlarging membership of researchers and clinicians at the Anschutz Medical Campus, which includes University of Colorado Hospital, Childrens Hospital Colorado, and the Veterans Administration Medical Center, as well as the Boulder campus, Colorado State University, the Colorado School of Mines, and business startups. This collaboration is designed to draw on the widest possible array of scientific exploration relevant to stem cell technology focused on the delivery of innovative therapies in Colorado and beyond.

ABOUT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators, and scientists at University of Colorado Hospital, Childrens Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical schools care, education, research, and community engagement, visit its web site.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information, including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications, including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Originally posted here:
AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore...

BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York – P&T Community

TEL AVIV, Israel, Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conference Center near Grand Central Terminal in New York, N.Y.

The investor meeting schedule is as follows:

7:45 am EST Registration and breakfast8:10-9:30 am EST Formal presentations

Location:

Convene Conference Center237 Park Avenue (on 46th St. between Park and Lex)New York, N.Y.(888) 730-7307

The event will feature a presentation by Talia Golan, MD, from The Chaim Sheba Medical Center,who will discuss the current treatment landscape as well as the unmet medical need for treating patients with metastatic pancreatic adenocarcinoma (PDAC). Dr. Golan will be available to answer questions at the conclusion of the event.

BioLineRx's management team will also provide an update on the COMBAT/KEYNOTE-202 triple combination study in metastatic PDAC under its collaboration with Merck. In addition, the management team will provide a comprehensive overview of the Company's other developments for BL-8040, as well as its second lead asset, AGI-134. BL-8040 is a novel short synthetic peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation. AGI-134, a synthetic Gal novel immunotherapy, is currently in Phase 1/2a development for solid tumors.

Talia Golan, MD is a clinician-scientist currently conducting translational laboratory research while also serving as medical director ofthe Phase I Unit and the Pancreatic Cancer (PC) Center at Sheba Medical Center in Tel Aviv, one of the leading medical centers in the world. Her clinical interest is in patients with pancreatic cancer. Dr. Golan's career goals include expertise in clinical medicine, translational laboratory research, and drug development. Dr Golan is PI on multiple early-phase trials on immune modulators. Her clinical and research expertise focuses on the understanding and treatment of hereditary pancreatic cancer patients. Dr. Golan is co-global PI of the first biomarker-selected (BRCA) Phase III clinical trial in PC, the POLO study.Dr. Golan's translational research lab, established in 2011, is an integral part of theSheba Pancreatic Cancer Program (SPCC). The research in the lab focuses on improving the standard of care options for pancreatic cancer patients by both finding targeted treatments tailored for each patient based on his own genetic background and developing state of the art early detection methodology. Disease heterogeneity and late detection are still the main challenges of pancreatic cancer treatment.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.For those who are unable to attend in person, a live webcast and replay of the event will be accessible here.If you would like to ask a question during the live Q&A portion of the event, please submit your request via email.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company'slead program, BL-8040, is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. BL-8040 is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. In addition, the Company has an ongoing collaboration agreement with Genentech, a member of the Roche Group, evaluating BL-8040 in combination with Genentech's atezolizumab in two Phase 1b/2 solid tumor studies.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being undergoing in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook,Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthyLifeSci Advisors, LLC+1-212-915-2564tim@lifesciadvisors.com

or

Tsipi HaitovskyPublic Relations+972-52-598-9892 tsipihai5@gmail.com

View original content:http://www.prnewswire.com/news-releases/biolinerx-to-host-investor-and-analyst-breakfast-meeting-on-december-5-2019-in-new-york-300965306.html

SOURCE BioLineRx Ltd.

Visit link:
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York - P&T Community

Thankful People — ‘He’s gonna owe me big’: Matthew McKee receives bone-marrow donation from twin sister Allee – Southeast Missourian

In late October, laughter permeated The Olson Family Garden at St. Louis Childrens Hospital as Matthew McKee got the chance to do something abnormal: run and play outside.

No one else covers what matters here like the Southeast Missourian from births to deaths and everything in between. Don't miss out. Support our mission.

More here:
Thankful People -- 'He's gonna owe me big': Matthew McKee receives bone-marrow donation from twin sister Allee - Southeast Missourian

Types of Adult Stem Cells – Stem Cell Institute

Stem cells reside in adult bone marrow and fat, as well as other tissues and organs of the body including the umbilical cord. These cells have a natural ability to repair damaged tissue, however in people with degenerative diseases they are not released quickly enough to fully repair damaged tissue. In the case of fat stem cells they may not be released at all. The process of actively extracting, concentrating and administering these stem cells has been shown in clinical trials to have beneficial effects in degenerative conditions. Few patients have access to clinical trials. We offer patients and their doctors access to these therapies now. Stem cell treatments are not covered by insurance.

Adult stem cells can be extracted from most tissues in the body, including the bone marrow, fat, and peripheral blood. They can also be isolated from human umbilical cords and placental tissue. Once the cells have been harvested, they are sent to the lab where they are purified and assessed for quality before being reintroduced back in the patient. Common types of adult stem cells are mesenchymal and hematopoietic stem cells.

Umbilical cord mesenchymal stem cells reside in the *umbilical cords of newborn babies. HUCT-MSC stem cells, like all post-natal cells, are adult stem cells.

The Stem Cell Institute utilizes cord-derived mesenchymal stem cells that are separated from the umbilical cord tissue. For certain indications, these cells are expanded into greater numbers at Medistem laboratory in Panama under very strict, internationally recognized guidelines.

Among many other things, mesenchymal stem cells from the umbilical cord tissue are known to help reduce inflammation, modulate the immune system and secrete factors that may help various tissues throughout the body to regenerate.

The bodys immune system is unable to recognize HUCT mesenchymal stem cells as foreign and therefore they are not rejected. Weve treated hundreds of patients with umbilical cord stem cells and there has never been a single instance rejection (graft vs. host disease). HUCT MSCs also proliferate/differentiate more efficiently than older cells, such as those found in the bone marrow and therefore, they are considered to be more potent.

Through retrospective analysis of our cases, weve identified proteins and genes that allow us to screen several hundred umbilical cord donations to find the ones that we know are most effective. We only use these cells and we call them golden cells.

We go through a very high throughput screening process to find cells that we know have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration.

Human umbilical cord tissue-derived mesenchymal stem cells (MSCs) that were isolated and grown in our laboratory in Panama to create master cell banks are currently being used in the United States.

These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchennes muscular dystrophy patients under US FDAs designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient)

The bone marrow stem cell is the most studied of the stem cells, since it was first discovered to in the 1960s. Originally used in bone marrow transplant for leukemias and hematopoietic diseases, numerous studies have now expanded experimental use of these cells for conditions such as peripheral vascular disease, diabetes, heart failure, and other degenerative disorders.

At Stem Cell Institute, we use purified autologous (patients own) mesenchymal stem cells from bone marrow in our spinal cord injury protocol along with umbilical cord tissue mesenchymal stem cells.

Fat stem cells are essentially sequestered and are not available to the rest of the body for repair or immune modulation. Fat derived stem cells have been used for successful treatment of companion animals and horses with bone and joint injuries for the last 10 years with positive results.

Experimental studies suggest fat derived stem cells not only can develop into new tissues but also suppress pathological immune responses as seen in autoimmune diseases. In addition to orthopedic conditions, Stem Cell Institute pioneered treating patients with osteoarthritis, rheumatoid arthritis, multiple sclerosis, and other autoimmune diseases using fat derived stem cells. However, we no longer use a patients own stem cells from fat because weve found that mesenchymal stem cells from umbilical cord tissue are superior.

Dr. Riordan published the first scientific article on treating humans (3 multiple sclerosis patients) with adipose-derived stem cells. We have treated many patients with adipose-derived mesenchymal stem cells in Panama but we no longer do so because we have found that umbilical cord-derived MSCs modulate the immune system and control inflammation better. HUCT MSCs also proliferate much more efficiently.

Articles Authored by our Doctors and Scientists about Fat Derived Stem Cells:

*All donated cords are the by-products of normal, healthy births. Each cord is carefully screened for sterility and infectious diseases under International Blood Bank standards.

See the original post here:
Types of Adult Stem Cells - Stem Cell Institute

Adult Leukemia: What You Need to Know – Dana-Farber Cancer Institute

Medically reviewed by Richard M. Stone, MD

More than 60,000 new cases ofadult leukemiaare diagnosed in the U.S. each year. Although it is one of the more common childhood cancers,leukemia occurs more often in older adults.

Leukemia is a cancer of the bodys blood-forming tissues that results in large numbers of abnormal or immature white blood cells. The main types of leukemia are:

AML causes the bone marrow to produce immature white blood cells (called myeloblasts). As a result, patients may have a very high or lowwhite blood cellcount, and lowred blood cellsandplatelets.

CLL is the second most common type of leukemia in adults. It is a type of cancer in which the bone marrow makes too many maturelymphocytes(a type of white blood cell).

ALL is a type of leukemia in which the bone marrow makes too many immaturelymphocytes. Similar to AML, the white blood cells can be high or low and oftentimes the platelets and red blood cells are low. This form of leukemia is more common in children than adults.

CML is usually a slowly progressing disease in which too many mature white blood cells are made in the bone marrow.

People with leukemia may experience:

Because these symptoms can be caused by a variety of other conditions, its important to check with your doctor if they arise.

While studies have shown men to be more atrisk than women, some other risk factors include:

While test procedures vary based on the type of leukemia, the two most common procedures are thecomplete blood count(CBC) test and the bone marrow aspiration biopsy.

CBC is a procedure used to check the redblood cell and platelet counts as well as the number and type of white bloodcells (the red cells carry oxygen, the white cells fight and prevent infection,and platelets control bleeding). A bone marrow aspiration biopsy involvesremoving a sample of bone marrow, including a small piece of bone by insertinga needle into the hipbone. The sample is then examined for abnormal cells.

Treatment for leukemia varies depending on the type and specific diagnosis.

The treatment for acute leukemias may be lengthy up to two years in ALL and is usually done in phases. The first phase, known as remission induction therapy, involves administering several chemotherapy drugs over a several-week period. The goal is to destroy as many cancer cells as possible to achieve a remission (in which cancer cells are undetectable, but small amounts are still present).

The second phase, known aspost-remission or consolidation therapy, seeks to kill leukemia cells thatremain after remission induction therapy. This phase may involve chemotherapyand/or a stem cell transplant.

Additional treatments may also be necessary. ALL patients, for example, may receive special treatment to prevent the disease from recurring in the spinal cord or brain.

The treatment for CML has been revolutionized by the advent of the oral medication imatinib and the second- and third-generation drugs known as tyrosine kinase inhibitors (TKIs). These are oral medications that work to inhibit the function of theBCR-ABLprotein. Many patients take these medications for the rest of their lives. In rare instances, a patient may require a stem cell transplant.

Some patients with CLL are recommended formonitoring and observation. Others,usually those with symptoms or low red cell or platelet counts, requiretreatment. Such treatment may involve intravenous chemotherapy, but often withoral therapy with pills that inhibit the function of a key protein, Brutonstyrosine kinase.

Treatments for leukemia can include:

Drugs that harness the immune system in fighting leukemia have shown considerable promise. Some monoclonal antibodies synthetic versions of immune system proteins are already in use to treat certain forms of leukemia and others are being studies in clinical trials.

Another form of immunotherapy, immune checkpoint inhibitors, which release a pent-up immune system attack on tumor cells, is being tested in several forms of leukemia. Cancer vaccines, which boost the immune systems ability to fight cancer, are being studied for use in leukemia.

CAR T-cell therapy, which uses modified immune system T cells to better target and kill tumor cells, has achieved impressive results in trials involving children and adults up to age 25 with relapsed ALL.

Research into new treatments for adult leukemia is moving along several tracks in addition to immunotherapy.

By tracking the specific abnormal genes within leukemia cells, physicians are increasingly able to tailor treatment to the unique characteristics of the disease in each patient. Targeted drugs such as imatinib and dasatinib, for example, are now used in treating patients with ALL whose leukemia cells have an abnormality known as the Philadelphia chromosome. Targeted agents including IDH or FLT3 inhibitors, which zero in on proteins made from mutated genes, have been approved to treat some patients with AML, while other such inhibitors are being tested in clinical trials.

New tests make it possible to detect ever smaller amounts of leukemia that remain after treatment. Investigators are exploring how these minute levels may influence a patients prognosis and how they might impact treatment.

Researchers are testing whether treatment periods for certain drugs can be safely reduced in some patients. For instance, studies are under way to determine if drugs such as imatinib, which are currently taken for life, can be safely stopped in some patients with CML. Researchers hope to test whether treating patients with CLL with the drug ibrutinib plus other medicine for a fixed amount of time is safe and effective.

Patients may consider treatment through a clinical trial.Dana-Farber currently has more than 30 clinical trials for adult leukemia. A national list of clinical trials is available atclinicaltrials.gov.

Go here to read the rest:
Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute